Advanced non-small-cell lung cancer: 'Triplets' better than 'doublets'?: Commentary

Nature Clinical Practice Oncology

Volumn 3, Issue 9, 2006, Pages 476-477

  Mountzios, Giannis ^a   Soria, Jean Charles ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; GEMCITABINE; PACLITAXEL;

ADVANCED CANCER; ANEMIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; FEASIBILITY STUDY; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS POTENTIAL; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; SHORT SURVEY; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; PACLITAXEL;

EID: 33748429719     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0585     Document Type: Short Survey

References (3)

1. Tyagi P (2005) Bevacizumab, when added to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced NSCLC: preliminary results from the ECOG 4599 trial. Clin Lung Cancer 6: 276-278
2. Delbaldo C et al. (2004) Benefit of adding a drug to a single agent or a two agent chemotherapy regimen in advanced NSCLC. JAMA 292: 470-484
3. Rosell R et al. (2002) Phase III randomised trial comparing paclitaxel/ carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: A cooperative multinational trial. Ann Oncol 13: 1539-1549